ZBIO

Zenas BioPharma, Inc. (ZBIO) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Zenas BioPharma is a clinical-stage biopharmaceutical company focused on immunology and inflammation (I&I) therapies. The company's lead asset, obexelimab, recently reported positive Phase 3 topline data for IgG4-Related Disease (IgG4-RD) in January 2026, with a Biologics License Application (BLA) planned for submission in Q2 2026. The company also advanced its orelabrutinib program for multiple sclerosis (MS) and acquired rights to two additional preclinical candidates (ZB021, ZB022) via a license agreement with InnoCare Pharma.

Key Financial Metrics

Note: Debt obligations include a $72.1 million senior secured term loan, $193.6 million convertible senior notes, and an $84.9 million royalty obligation.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero from $10.0 million in Q1 2025. The prior period revenue was a one-time upfront payment from the Zai Lab license agreement; no similar milestones were achieved in Q1 2026.
• Expense Surge: Operating expenses increased by $30.0 million (63.4%). Research and Development (R&D) expenses rose $25.5 million to $60.4 million, driven by increased clinical trial and manufacturing costs for obexelimab and the initiation of orelabrutinib trials. General and Administrative (G&A) expenses increased $4.5 million due to headcount growth and professional fees.
• Capital Raise & Debt: The company significantly altered its capital structure in Q1 2026:
  • Issued $200.0 million in 2.50% Convertible Senior Notes due 2032.
  • Secured a $75.0 million Tranche A draw under a $250.0 million senior secured term loan facility with Pharmakon.
  • Completed a follow-on equity offering of 5.0 million shares and sold 2.8 million shares under its ATM program, raising approximately $165.5 million in net proceeds.
• Liquidity Improvement: Cash and investments increased by $358.0 million quarter-over-quarter, primarily due to the financing activities listed above.

Guidance, Outlook, and Risks

• Clinical Outlook: Management expects to report topline results for the SunStone trial (obexelimab in SLE) in Q4 2026. A Phase 3 program for SLE may be initiated in H1 2027 based on these results. Orelabrutinib Phase 3 trials in PPMS and naSPMS are ongoing.
• Liquidity Runway: Management estimates existing cash and investments ($718.5 million) will fund operations into 2029. This projection assumes the receipt of potential milestone payments from Royalty Pharma ($75 million) and additional term loan tranches ($75 million) contingent upon FDA approval of obexelimab for IgG4-RD.
• Subsequent Milestone Payment: On May 13, 2026, the company announced the achievement of a regulatory milestone for ZB021, triggering a $20.0 million payment obligation to InnoCare Pharma.
• Risks: Key risks include the high cost of clinical development, the uncertainty of regulatory approvals, the impact of tariffs on supply chains (particularly from China), and the ability to service significant new debt obligations (term loan and convertible notes) without product revenue.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the new Pharmakon term loan covenants, specifically the minimum liquidity requirement and future revenue covenants tied to Tranche B/C approval.
• Convertible Note Dilution: Review the conversion terms of the $200 million notes (initial conversion price ~$26.50) and the potential dilution impact if the stock price exceeds 130% of the conversion price.
• Royalty Obligation Accounting: Confirm the effective interest rate (32.3%) and future cash flow projections for the Royalty Pharma agreement, which is accounted for as a debt liability.
• Subsequent Events: Account for the $20.0 million InnoCare milestone payment triggered in May 2026 and the additional $30.0 million in convertible notes and $15.0 million in equity raised via the overallotment option in April 2026.
• Supply Chain Exposure: Assess the impact of U.S.-China trade tensions and tariffs on the cost of goods, given reliance on Chinese CMOs for obexelimab and orelabrutinib.